OTC Watch

All stocks / PTIX

Protagenic Therapeutics, Inc.\new PTIX

Protagenic Therapeutics, Inc.\new (PTIX): a late 10-Q notice in August 2026 and the latest annual figures in plain language. Each fact links to its SEC filing.

Estimated floatLate filing OTCQBNew York, USA
Live quote on OTC Markets

Market listing

Full name
PROTAGENIC THERAPEUTICS INC
Market tier
OTCQB
Trading status
Active
Last trade
Nov 16
Website
protagenic.com/
Source: Stockwatch, 2026-11-17

News headlines

Protagenic Therapeutics Announces Private Placement of Up to $5 Million to Advance PT00114 into Its First U.S. Clinical Trial in Generalized Anxiety Disorder
2026-11-11 08:30 · News Release
Protagenic Therapeutics Receives FDA Pre-IND Feedback Supporting New IND for PT00114 in Generalized Anxiety Disorder
2026-08-20 08:30 · News Release
Protagenic Therapeutics' Lead Candidate PT00114 Attenuated Chronic Stress Responses in a Well-Established Rodent Model
2026-06-30 08:30 · News Release
Protagenic Therapeutics Engages Floyd Regulatory Strategic Consulting as Regulatory Affairs Advisor and Danforth Health as Strategic Operations Partner
2026-05-19 08:15 · News Release
Protagenic Therapeutics Appoints Industry Veteran Bill Nichols Jr. as President to Accelerate Advancement of First-in-Class TCAP Pathway Therapy PT00114
2026-04-23 08:17 · News Release
Protagenic Therapeutics Completes Phytanix Separation, Strengthens Balance Sheet and Repositions the Company Around PT00114
2026-03-17 08:00 · News Release
Protagenic Therapeutics Upgrades from OTC Pink to OTCQB Venture Market
2026-03-10 08:00 · News Release
Results from Phase 1 Multiple-Dose Study of PT00114
2025-12-09 08:46 · News Release
Headlines only, with links to the full item. Company press releases are written by the company.

The financial report, and what it means

Annual figures to 2026-03-31
The report says
Revenue
$0
Net income
$1,367,977
What it means

It earned more than it spent

Steady

After all costs, the company kept $1.4 million as profit in the year.

The report says
Cash and cash equivalents
$1,509,178
Net cash used in operating activities
($2,806,800)
What it means

The cash could run out soon

Under strain

It had $1.5 million in the bank and used about $233,900 a month. At that pace the money lasts about 6 months unless it borrows or sells more shares.

The report says
Total assets
$3,650,370
Total liabilities
$1,031,479
What it means

It owns more than it owes

Steady

Everything the company owns adds up to $3.7 million. Its debts and unpaid bills add up to $1 million. That is about $0.28 owed for every $1 owned.

What this adds up to

1 of 3 checks show strain. The cash could run out soon. These are facts from the company's own reports, not a recommendation.

Signals

Estimated float2026-11-06

Estimated float about 1,736,675 shares as of 2026-11-06: 1,810,208 outstanding minus 73,533 held by 1 reporting insider(s).

Rule: Estimated: shares outstanding minus the latest holdings insiders reported on Forms 3/4/5. Holders of 5% or more (13D/13G) are not yet subtracted. Source record

Late filing2026-08-14

Filed NT 10-Q on 2026-08-14: notice that a periodic report is late.

Rule: Late-filing notice (Form NT 10-K or NT 10-Q) in the last 12 months. Source record

Late filing2026-06-30

Filed NT 10-K on 2026-06-30: notice that a periodic report is late.

Rule: Late-filing notice (Form NT 10-K or NT 10-Q) in the last 12 months. Source record

Late filing2026-02-18

Filed NT 10-Q on 2026-02-18: notice that a periodic report is late.

Rule: Late-filing notice (Form NT 10-K or NT 10-Q) in the last 12 months. Source record

Shares outstanding

Source: SEC filings
2025-12-31
1.9M
2026-03-05
1.8M
2026-03-31
1.8M
2026-06-30
1.8M
2026-08-14
1.8M
2026-08-19
1.8M
2026-09-30
1.8M
2026-11-06
1.8M

Price chart

Chart by TradingView. We do not store or publish prices. Live quote on OTC Markets

Recent filings

2026-11-06 8-K8-K
2026-11-06 10-Q10-Q
2026-08-24 44
2026-08-20 44
2026-08-20 8-K8-K
2026-08-20 44
2026-08-19 10-Q10-Q
2026-08-14 10-K10-K
2026-08-14 NT 10-QNT 10-Q
2026-08-12 44
2026-08-10 44
2026-08-06 44

Common questions about PTIX

Does PTIX file reports with the SEC?

Yes. Protagenic Therapeutics, Inc.\new files with the SEC under company number 0001022899. The most recent filing we hold is a 8-K dated 2026-11-06.

Source record

How many PTIX shares are outstanding?

1,810,208 shares as of 2026-11-06, as reported to the SEC.

Source record

Has PTIX filed reports late?

Yes. In the last 12 months it filed 3 late-filing notices, most recently a NT 10-Q on 2026-08-14. A notice means a report was not ready on time; check whether the report followed.

Source record

Who runs Protagenic Therapeutics, Inc.\new?

Officers named in its insider filings: Garo H Armen (EXEC. CHAIR & PRINCIPAL OFF).

Source record

Is Protagenic Therapeutics, Inc.\new making money?

After all costs, the company kept $1.4 million as profit in the year. (Annual figures to 2026-03-31. Facts from the company's own report, not a recommendation.)

Source record